Area of research
Surgery · Radiology, Nuclear Medicine and Imaging
Research interest
Prof Nicholls’s research broadly focuses on developing new strategies to reduce the risk of heart disease, involving translational research spanning preclinical human and clinical trials.
Topical Reconstituted High-Density Lipoproteins Elicit Anti-Inflammatory Effects in Diabetic Wounds.
Clonal hematopoiesis of indeterminate potential (CHIP): A need for standardized definition and criteria for translational research studies
Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a)
Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk
The Global Syndemic of Modifiable Cardiovascular Risk Factors Projected From 2025 to 2050
A national study of infective endocarditis models of care in Australia.
Can Australia Tackle its Failure in Research Translation to Reduce Cardiovascular Disease, Improve Equity and Deliver Better Health and Economic Outcomes?
Global burden of cardiovascular diseases: projections from 2025 to 2050
Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia
Cardiovascular-Liver-Metabolic Health: Recommendations in Screening, Diagnosis, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Cardiovascular Disease via Modified Delphi Approach
The Integration of Clinical Trials With the Practice of Medicine
Personalized Intervention Based on Early Detection of Atherosclerosis
Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MI
Obesity in the Asia-Pacific Region: Current Perspectives
Modernizing the Data Infrastructure for Clinical Research to Meet Evolving Demands for Evidence
National Hypertension Taskforce of Australia: a roadmap to achieve 70% blood pressure control in Australia by 2030
Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trial
ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction
Integrating Cardio-Oncology Across the Research Pipeline, Policy, and Practice in Australia—An Australian Cardiovascular Alliance Perspective
Computed tomographic angiography measures of coronary plaque in clinical trials: opportunities and considerations to accelerate drug translation
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
Proteomics and lipidomics in atherosclerotic cardiovascular disease risk prediction
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial
Trends and predictions of metabolic risk factors for acute myocardial infarction: findings from a multiethnic nationwide cohort
Australian Atherosclerosis Society Position Statement on Lipoprotein(a): Clinical and Implementation Recommendations
When Cancer and Cardiovascular Disease Intersect: The Challenge and the Opportunity of Cardio-Oncology
Incorporating a polygenic risk score-triaged coronary calcium score into cardiovascular disease examinations to identify subclinical coronary artery disease (ESCALATE): Protocol for a prospective, nonrandomized implementation trial
Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction
Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes
World Heart Federation Cholesterol Roadmap 2022